Literature DB >> 26459269

Rotavirus VP7 epitope chimeric proteins elicit cross-immunoreactivity in guinea pigs.

Bingxin Zhao1, Xiaoxia Pan2, Yumei Teng1, Wenyue Xia1, Jing Wang1, Yuling Wen1, Yuanding Chen3.   

Abstract

VP7 of group A rotavirus (RVA) contains major neutralizing epitopes. Using the antigenic protein VP6 as the vector, chimeric proteins carrying foreign epitopes have been shown to possess good immunoreactivity and immunogenicity. In the present study, using modified VP6 as the vector, three chimeric proteins carrying epitopes derived from VP7 of RVA were constructed. The results showed that the chimeric proteins reacted with anti-VP6 and with SA11 and Wa virus strains. Antibodies from guinea pigs inoculated with the chimeric proteins recognized VP6 and VP7 of RVA and protected mammalian cells from SA11 and Wa infection in vitro. The neutralizing activities of the antibodies against the chimeric proteins were significantly higher than those against the vector protein VP6F. Thus, development of chimeric vaccines carrying VP7 epitopes using VP6 as a vector could be a promising alternative to enhance immunization against RVAs.

Entities:  

Keywords:  VP6; VP7 epitope chimeric vaccine; foreign epitope presenting vector; neutralizing activity; rotavirus

Mesh:

Substances:

Year:  2015        PMID: 26459269      PMCID: PMC8200902          DOI: 10.1007/s12250-015-3620-5

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  31 in total

1.  Rotavirus vaccines. WHO position paper – January 2013.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2013-02-01

2.  A new rotavirus VP6-based foreign epitope presenting vector and immunoreactivity of VP4 epitope chimeric proteins.

Authors:  Yumei Teng; Bingxin Zhao; Xiaoxia Pan; Yuling Wen; Yuanding Chen
Journal:  Viral Immunol       Date:  2014-04-04       Impact factor: 2.257

3.  Characteristics and location of cross-reactive and serotype-specific neutralization sites on VP7 of human G type 9 rotaviruses.

Authors:  C Kirkwood; P J Masendycz; B S Coulson
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

4.  Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb.

Authors:  Ningguo Feng; Jeffrey A Lawton; Joana Gilbert; Nelly Kuklin; Phuoc Vo; B V Venkataram Prasad; Harry B Greenberg
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

5.  Efficacy of the oral pentavalent rotavirus vaccine in Mali.

Authors:  Samba O Sow; Milagritos Tapia; Fadima C Haidara; Max Ciarlet; Fatoumata Diallo; Mamoudou Kodio; Moussa Doumbia; Rokiatou D Dembélé; Oumou Traoré; Uma U Onwuchekwa; Kristen D C Lewis; John C Victor; A Duncan Steele; Kathleen M Neuzil; Karen L Kotloff; Myron M Levine
Journal:  Vaccine       Date:  2012-04-27       Impact factor: 3.641

6.  Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.

Authors:  K Zaman; Duc Anh Dang; John C Victor; Sunheang Shin; Md Yunus; Michael J Dallas; Goutam Podder; Dinh Thiem Vu; Thi Phuong Mai Le; Stephen P Luby; Huu Tho Le; Michele L Coia; Kristen Lewis; Stephen B Rivers; David A Sack; Florian Schödel; A Duncan Steele; Kathleen M Neuzil; Max Ciarlet
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

Review 7.  Vaccines for preventing rotavirus diarrhoea: vaccines in use.

Authors:  Karla Soares-Weiser; Harriet Maclehose; Hanna Bergman; Irit Ben-Aharon; Sukrti Nagpal; Elad Goldberg; Femi Pitan; Nigel Cunliffe
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

8.  Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua.

Authors:  Manish Patel; Cristina Pedreira; Lucia Helena De Oliveira; Jacqueline Tate; Maribel Orozco; Juan Mercado; Alcides Gonzalez; Omar Malespin; Juan José Amador; Jazmina Umaña; Angel Balmaseda; Maria Celina Perez; Jon Gentsch; Tara Kerin; Jennifer Hull; Slavica Mijatovic; Jon Andrus; Umesh Parashar
Journal:  JAMA       Date:  2009-06-03       Impact factor: 56.272

9.  Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity.

Authors:  J W Burns; M Siadat-Pajouh; A A Krishnaney; H B Greenberg
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

10.  Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.

Authors:  Celina G Vega; Marina Bok; Anastasia N Vlasova; Kuldeep S Chattha; Silvia Gómez-Sebastián; Carmen Nuñez; Carmen Alvarado; Rodrigo Lasa; José M Escribano; Lorena L Garaicoechea; Fernando Fernandez; Karin Bok; Andrés Wigdorovitz; Linda J Saif; Viviana Parreño
Journal:  PLoS Pathog       Date:  2013-05-02       Impact factor: 6.823

View more
  1 in total

1.  Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine.

Authors:  Sanjeev Agarwal; Neha Sahni; John M Hickey; George A Robertson; Robert Sitrin; Stanley Cryz; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2019-08-07       Impact factor: 3.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.